TLRY dividend history

Record Fiscal Year Net Revenue of $915 Million, Record Gross Profit, Consistent Adjusted Gross Margin3 and Record Adjusted EBITDA5 Highlights the Strength of Tilray’s Scaled Businesses and Profitable Growth Strategy International Medical Cannabis Revenue Increased 34% for the Fiscal Year, Reinforcing Tilray's Leadership Across Europe and Expanding Patient Access at Scale BrewDog Acquisition Ignited the Global Expansion of Tilray’s Beverage Platform, Unlocking New Growth Through the Power of Brands, Hospitality and Consumer Experiences Disciplined Capital Allocation Strengthens Balance Sheet with Approximately $235 Million in Cash, Restricted Cash and Marketable Securities1; Net Debt2 Redu

Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

VANCOUVER, BC, Nov. 23, 2021 /PRNewswire/ - Hollister Biosciences Inc. (CSE:HOLL) (OTC:HSTRF) (FRANKFURT: HOB) (the "Company" or "Hollister Biosciences") today announced results of its 2021 Annual General and Special Shareholder Meeting (the "Meeting") held on November 22, 2021. All of the matters put forward before the Company's shareholders for consideration and approval, as listed in the management information circular of the Company dated October 18, 2021 (the "Circular"), were approved by the requisite majority of votes cast at the Meeting. This includes the election of all six (6) Board of Director nominees listed in the Circular: Jakob Ripshtein, Jacob Cohen, Eula Adams, Lily Dash,

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- The legalization of medical cannabis and its decriminalization in certain countries has led to a significant decrease in the black market. People are now choosing to legally purchase their cannabis for medical as well as adult use. Typically, medical marijuana is used for the treatment of chronic conditions, such as cancer, arthritis, and neurological conditions, such as anxiety, depression, epilepsy, as well as Parkinson's, and Alzheimer's disease. In the U.S, New Jersey became the most recent state where two key legislative budget committees advanced a recreational cannabis implementation measure. New Jersey voters legalized an adult-use marijuana